drugset
drugset / Trial / NCT00394082

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

NCT00394082 ↗

Phase 2 Completed 50 enrolled Celgene Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.

Timeline

Start
2006-06-01
Primary completion
2009-09-01
Completion
2011-02-01

Publications

  • Background Danso M, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Presented at 2008 ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL. Abstract No. 1075.

Drugs

EvaluationDrugModalityDoseRoute
Subject ABI-007 Unknown 125 mg/m2 Intravenous
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

breast cancer